Vertex Pharmaceuticals Inc / Ma: Form 10-Q for the period ended Jun 30, 2020
Filed with the SEC on Jul 31, 2020 and accepted by EDGAR at Jul 31, 2020, 16:18 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-04-01 to 2020-06-30 | $1.52bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2020-01-01 to 2020-06-30 | $3.04bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2020-04-01 to 2020-06-30 | $184.5m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2020-01-01 to 2020-06-30 | $347.0m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2020-04-01 to 2020-06-30 | $420.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2020-01-01 to 2020-06-30 | $869.5m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2020-04-01 to 2020-06-30 | $191.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2020-01-01 to 2020-06-30 | $374.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2020-04-01 to 2020-06-30 | $718.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2020-01-01 to 2020-06-30 | $1.44bn | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2020-04-01 to 2020-06-30 | −$12.5m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2020-01-01 to 2020-06-30 | $42.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-04-01 to 2020-06-30 | $837.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months2020-01-01 to 2020-06-30 | $1.44bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-04-01 to 2020-06-30 | $3.18 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2020-01-01 to 2020-06-30 | $5.46 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-04-01 to 2020-06-30 | $3.22 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2020-01-01 to 2020-06-30 | $5.54 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2020-04-01 to 2020-06-30 | 263,403,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2020-01-01 to 2020-06-30 | 263,746,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2020-01-01 to 2020-06-30 | $1.85bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2020-01-01 to 2020-06-30 | $37.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2020-01-01 to 2020-06-30 | $300.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2020-06-30 | $4.83bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-06-30 | $6.69bn | us-gaap:AssetsCurrent |
| Total assets | At period end2020-06-30 | $10.22bn | us-gaap:Assets |
| Current liabilities | At period end2020-06-30 | $1.80bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-06-30 | $2.70bn | us-gaap:Liabilities |
Source: SEC EDGAR, the filing index for accession 0000875320-20-000030. Last ingested by Listed: Nov 6, 2026, 12:56 ET. Listed shows no prices and gives no investment advice.